文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

COVID-19疫苗安全性监测的规划

Planning for COVID-19 vaccines safety surveillance.
PubMed 文献 · Vaccine · 2020-07-10

COVID-19疫苗是遏制疫情的关键工具,正以前所未有的全球合作和加速时间表开发。在确保全球公平获取的同时,各国需紧急准备疫苗安全性监测,以调查特殊关注不良事件(AESI)和免疫接种后不良事件,并计算背景发生率。主动监测系统应计算AESI的背景发生率,建立或加强主动监测系统(包括中低收入国家),使用标准化病例定义和全球标准,并制定疫苗安全沟通计划。

要点

  • 各国需紧急准备COVID-19疫苗安全性监测,以调查AESI和免疫接种后不良事件。
  • 主动监测系统应在疫苗推广前计算AESI的背景发生率,背景率因地区、人群和病例确认方法而异。
  • 需建立或加强主动监测系统(包括中低收入国家),使用标准化病例定义和全球标准,并制定疫苗安全沟通计划。

核心结论

  • 扩大全球疫苗安全系统以满足COVID-19和其他应急及常规使用疫苗的需求是当前的优先事项。

研究设计与样本

  • 原文未报告

主要发现

  • COVID-19疫苗正以前所未有的全球合作和加速时间表开发,以实现WHO紧急使用列表。
  • 安全性监测必须能够调查AESI和免疫接种后不良事件,以确定疫苗获益-风险概况的变化。
  • AESI的背景发生率因地区、人群和病例确认方法不同而差异巨大。

关键数值与推荐

  • 主动监测系统应在疫苗推广前计算AESI的背景发生率。
  • 应建立或加强主动监测系统(包括中低收入国家)以计算背景发生率。
  • 使用标准化病例定义和全球AESI标准有助于协调统一。
  • 应制定疫苗安全沟通计划。

临床怎么用

  • 在COVID-19疫苗推广前,各国应建立或加强主动监测系统以计算AESI背景发生率。
  • 使用标准化病例定义和全球标准进行AESI监测,并制定疫苗安全沟通计划。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 vaccines are the most important tool to stem the pandemic. They are being developed with unprecedented global collaboration and accelerated timelines to achieve WHO Emergency Use Listing, while using regulatory pathways through national regulatory authorities. Alongside preparations to ensure equitable access to the vaccines among people globally, preparations must be made within countries for COVID-19 vaccines safety surveillance on an urgent basis. Safety surveillance must be capable of investigating adverse events of special interest (AESI) and adverse events following immunization to determine a change in the benefit-risk profile of the vaccine, and to be able to anticipate coincidental events that might be attributed to the vaccine. Active surveillance systems should calculate the incidence of background rates of AESI prior to vaccine roll out. These background rates vary tremendously across regions, populations and case ascertainment methods. Active surveillance systems must be established or strengthened now, (including in LMIC), to calculate the background rates. Utilizing standardized case definitions and global standards for AESI will help in harmonization. Vaccine safety communication plans should be developed. Expanding the global vaccine safety system to meet the needs of COVID-19 and other emergency and routine use vaccines is a priority currently.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. Vaccine. 2020. PMID: 32684499. doi:10.1016/j.vaccine.2020.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。